Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

NurExone Biologic Inc. operates as a biotech company. The Company develops novel, biologic, and minimal-invasive treatment for spinal cord injury and traumatic brain injury. NurExone Biologic serves customers worldwide.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

BioLineRx Ltd. is a biopharmaceutical development company. The Company develops clinical-stage therapeutic pharmaceutical drugs.

<ul><li>BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.</li><li>The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.</li><li>Gloria Biosciences has delayed the start of its motixafortide studies in Asia and the path forward is unclear.</li></ul>

BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.Gloria Biosciences has delayed the start of its motixafortide studies in Asia and the path forward is unclear.

BLRX: Stem Cell Mobilization Presentation at ASH

Oramed Pharmaceuticals  / Equity Bottom-Up

Oramed Pharmaceuticals, Inc. is a pharmaceutical company focused on the development of oral delivery solution. The Company is developing orally ingestible insulin capsules for the treatment diabetes as well as delivery solutions for other drugs and vaccines.

<ul><li>ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space.</li><li> ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments.</li><li>The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid.</li></ul>

ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments.The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid.

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Freightos Limited provides online freight shipping marketplace and platform. The Company through its platform offers freight comparison, booking, and management services. Freightos serves customers worldwide.

<ul>
  <li>
<a href="https://smartkarma.com/entities/freightos-ltd">Freightos </a>is a first-mover in the digitization of the global freight industry, operating a SaaS-enabled marketplace that connects carriers, forwarders, and shippers, driving transparency and efficiency in a traditionally opaque market.</li>
  <li>The company is demonstrating strong top-line growth, evidenced by a 28.86% 3-year revenue CAGR and 23 consecutive quarters of record transaction volumes. However, it remains significantly unprofitable, with substantial cash burn as it invests in scaling its platform.</li>
  <li>Future success hinges on achieving operating leverage and scaling its network to reach profitability. The company is targeting adjusted EBITDA breakeven by the fourth quarter of 2026, a key catalyst for the stock.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Freightos is a first-mover in the digitization of the global freight industry, operating a SaaS-enabled marketplace that connects carriers, forwarders, and shippers, driving transparency and efficiency in a traditionally opaque market.
  The company is demonstrating strong top-line growth, evidenced by a 28.86% 3-year revenue CAGR and 23 consecutive quarters of record transaction volumes. However, it remains significantly unprofitable, with substantial cash burn as it invests in scaling its platform.
  Future success hinges on achieving operating leverage and scaling its network to reach profitability. The company is targeting adjusted EBITDA breakeven by the fourth quarter of 2026, a key catalyst for the stock.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Independent in-depth research from Finimize, Finimize

Finimize Research

Independent in-depth research from Finimize

Finimize

Finimize is the #1 information platform for modern investors. We empower people to become smarter investors with bitesize insights from world-class analysts. 1 million+ strong community, 250 partners.

Cross Asset Strategy

<ul>
<li>Technological revolutions follow a sequence: they start with a disruptive “installation phase”, then go through a critical “turning point”, and are finally followed by a “deployment phase”.</li>
<li>According to Carlota Perez, AI isn’t the start of a new technological revolution: it’s a critical milestone in the current, longstanding “information and telecommunication” revolution.</li>
<li>Being aware of different phases is valuable when investing. It can help you play the contrarian card – staying cautious during the frenzy and making bolder bets during the downturns.</li>
</ul>


Technological revolutions follow a sequence: they start with a disruptive “installation phase”, then go through a critical “turning point”, and are finally followed by a “deployment phase”.
According to Carlota Perez, AI isn’t the start of a new technological revolution: it’s a critical milestone in the current, longstanding “information and telecommunication” revolution.
Being aware of different phases is valuable when investing. It can help you play the contrarian card – staying cautious during the frenzy and making bolder bets during the downturns.


AI And Investing In The New Technological Revolution